Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||X-ray contrast agents|
|Abstract:||Compounds of the general formula: ##STR1## (where R is a group --CH(CH.sub.2 OH).sub.2 or --CH.sub.2 CH(OH)CH.sub.2 OH and A is a group --CH.sub.2 CH(OH)CH.sub.2 -- or --CH.sub.2 CH(OH)CH(OH)CH.sub.2 --) possess a package of favourable parameters which render them of particular use not only in all forms of intravascular visualisation but also in myelography. The compounds are prepared by reaction of an appropriate 5-acetylamino-N,N'-bis(hydroxypropyl)-2,4,6-triiodoisophthalamide with an agent effective to introduce the appropriate hydroxyalkylene group such as for example epichlorohydrin or 1,4-dichloro-2,3-dihydroxybutane.|
|Inventor(s):||Hansen; Per-Egil (Dalbo, NO), Holtermann; Hugo (Hovik, Baerum, NO), Wille; Knut (Oster.ang.s, NO)|
|Assignee:||Nycomed Imaging AS (Oslo, NO)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||8231796||Nov 08, 1982|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0108638||► subscribe||97C0101||Belgium||► subscribe|
|European Patent Office||0108638||► subscribe||SPC/GB93/150||United Kingdom||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.